Followers | 31 |
Posts | 2649 |
Boards Moderated | 0 |
Alias Born | 10/28/2013 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, January 10, 2014 10:11:45 AM
I think the deal was that the review board recommended an early approval, with a pretty clear vote, and the FDA decided no. Protests and a lawsuit followed. One of the points in the lawsuit was that one of the people in the FDA that voted against the early approval was associated with a direct competitor.
Not sure it makes sense to anticipate a problem Flipper. But if something similar were to come about, it would make sense to contact the same legal firm that handled that lawsuit and also the major players that initiated the lawsuit. Since there were also protests against the FDA, we could track down the major players there. Probably best to locate the ones that don't have a bunch of stock in Dendrion.
But I just did a quick read on that last week. Could be remembering things wrong... and I don't know what the outcome of the trial was, nor whether there really was anything improper by the FDA. I do know that the path is paved for such action.
Hate to bring up Provenge because some consider it a failure. (It is an immunotherapy similar to DCVax-L for prostate). However, the failure is due to the high production cost. NWBO focused on production costs and is able to mfg DCVax at about 1/3 the cost of Provenge. That is a huge!!!!! difference!!!!!
So NWBO will likely grow into a large and successful company on it's own right if it gets through these trials. For that reason it might not make sense to sell all your shares if and when approval comes.
Further: By having parallel clinicals in Europe, NWBO gives a second path for approval. But it also creates a situation where the FDA would look very suspect if the results were good and approval was denied... because if Europe approves the therapy and the number of patients skyrockets, and the results are good and widely known, which they would be... then the world would turn and look the FDA in the eye and ask what is going on?
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM